Showing 1–20 of 28 resultsSorted by latest
-
On demand upon order placementThis competitive intelligence report about Tissue Factor-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting tissue factor.€ 200.00
-
On demand upon order placementThis competitive intelligence report about CD38-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting CD38.€ 300.00
-
On demand upon order placementThis competitive intelligence report about TROP-2-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting TROP-2.€ 300.00
-
On demand upon order placementThis competitive intelligence report about Nectin-4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting nectin-4.€ 200.00
-
On demand upon order placementThis competitive intelligence report about CCR8-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting CCR8.€ 300.00
-
On demand upon order placementThis competitive intelligence report about EpCAM-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting EpCAM.€ 200.00
-
On demand upon order placementThis competitive intelligence report about B7-H4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting B7-H4.€ 300.00
-
On demand upon order placementThis competitive intelligence report about Mesothelin-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in R&D targeting mesothelin€ 300.00
-
On demand upon order placementThis competitive intelligence report about c-Met-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting c-Met.€ 300.00
-
On demand upon order placementThis competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting Her3.€ 300.00
-
August of 2025This competitive intelligence report about DLL3-Targeted Therapy provides a competitor evaluation in the field of product candidates targeting delta-like ligand 3 (DLL3) as of August of 2025.€ 300.00
-
August of 2025This competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.€ 300.00
-
July of 2025This competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.€ 400.00
-
July of 2025This competitive intelligence report about Fibroblast Activation Protein (FAP) Targeted Therapy provides a competitor evaluation in the field of product candidates targeting Fibroblast Activation Protein (FAP) as of July of...€ 300.00
-
July of 2025This competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of...€ 200.00
-
July of 2025This competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as...€ 200.00
-
July of 2025This competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
June of 2025Landscape analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective...€ 2600.00
-
March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00